Сперидан®

General characteristics. Structure:

Active agent - рисперидон 1 mg, 2 mg or 4 mg.
Excipients: microcrystallic cellulose, lactose anhydrous, magnesium stearate, starch prezhelatinizirovanny, gipromelloza, macrogoal 6000, titanium dioxide.
Description: Sneridan of 1 mg
Biconvex oval tablets of white color with a notch, 8 x 5 mm Sneridan of 2 mg
Biconvex oval tablets of white color with a notch, 10 x 5 mm Speridan of 4 mg
Biconvex oval tablets of white color with a notch, 14 x 7,5 mm

Pharmacological properties:

Antipsychotic means (neuroleptic) derivative of a benzizoksazol; renders also sedative, antiemetic and hypothermal action. The selection monoaminergichesky antagonist, possesses a high tropnost to serotonergic 5-HT2 and to dofaminergichesky 02 receptors, contacts also alfa1-adrenoceptors and at a little smaller affinity with Hi-gistaminergicheskimi and alfag-adrenergic receptors. Does not possess a tropnost to holinoretseptor Antipsychotic action is caused by blockade of dopamine 02 receptors of mesolimbic and mesocortical system. Sedative action is caused by blockade of adrenoceptors of a reticular formation of a trunk of a brain; antiemetic action - blockade dopamine D2-peuenTopoB of a trigger zone of the emetic center; hypothermal action - blockade of dopamine receptors of a hypothalamus. Reduces productive symptomatology (nonsense, hallucinations), automatism. Causes smaller suppression of motor activity and to a lesser extent induces a katalepsy, than classical anti-psychotics (neuroleptics).
The balanced central antagonism to serotonin and dopamine can reduce risk of emergence of extrapyramidal symptomatology.
Risperidon can cause dozozavisimy increase in concentration of prolactin in plasma.

Pharmacokinetics. Absorption. At intake of drug it is absorbed quickly and completely, at the same time food does not influence completeness and speed of absorption. The maximum concentration in plasma is reached in 1-2 hours. Equilibrium concentration of a risperidon in an organism at most of patients is reached within 1 day, 9-hydroxy-risperidona - in 4-5 days. Concentration of a risperidon in plasma are proportional to a drug dose (within therapeutic doses).
Distribution. Drug is quickly distributed, gets into the central nervous system, breast milk. Distribution volume - 1.1 l/kg. Communication with proteins of plasma (with an alpha 1 glycoprotein and albumine) a risperidona - 90%, 9-hydroxy-risperidona - 77%. Metabolism. CYP2D6 cytochrome to an active metabolite - 9-hydroxy-risperidon is metabolized by enzyme, (рисперидон and 9-hydroxies-risperidon make active antipsychotic fraction). Some other way metabolism N-dealkylation is. Removal. The elimination half-life of a risperidon makes 3 hours, the elimination half-life of 9-hydroxy-risperidona - is brought by kidneys, out of them 21 h 70% of drug - 35-45% - in the form of pharmacological active fraction; with bile 14% of drug are removed.
At a single dose high levels of active concentration in plasma and slow removal at elderly patients and at patients with a renal failure are noted.

Indications to use:

Schizophrenia (acute and chronic) and other psychotic states with productive and/or negative symptomatology.
Affective frustration at various mental diseases.
Behavioural frustration at patients with dementia at manifestation of symptoms of aggression (fits of anger, physical abuse), at activity disturbances (excitement, nonsense) or psychotic symptoms.
As drug of auxiliary therapy (as the mood stabilizer) - behavioural frustration at teenagers since 15 years and adult patients with the reduced intellectual level or a delay of intellectual development, in cases if the destructive behavior (aggression, impulsiveness, an autoaggression) is the leader in a clinical picture of a disease.
As auxiliary therapy at treatment of manias at bipolar disorders.

Route of administration and doses:

Schizophrenia.
Adults and children are more senior than 15 years. Speridan can be appointed one or two times a day. An initial dose - 2 mg a day. For the second day it is necessary to increase a dose to 4 mg a day. From this point the dose can or be kept at the previous level, or to correct individually if necessary. Usually optimum dose are 4-6 mg a day. In some cases slower increase in a dose and lower the initial and supporting doses can be justified.
Doses higher than 10 mg a day did not show higher performance in comparison with smaller doses and can cause emergence of extrapyramidal symptoms. Because safety of doses higher than 16 mg a day was not studied, doses are higher than this level it is impossible to apply.
Data on use for treatment of schizophrenia at children are younger than 15 years are absent. Elderly patients. The initial dose of 0.5 mg on reception twice a day is recommended. It is possible to increase a dosage individually on 0.5 mg twice a day to 1-2 mg twice a day.
Diseases of a liver and kidneys. The initial dose of 0.5 mg on reception 2 times a day is recommended. It is gradually possible to increase this dose to 1-2 mg by reception twice a day. Abuse   of medicines or medicinal dependence the recommended daily dose of drug - 2-4 mg. Behavioural frustration at patients with dementia.
The initial dose on 0,25 mg on reception twice a day is recommended (it is necessary to use an adequate dosage form). If necessary it is possible to increase a dosage individually on 0:25 mg 2 times a day, not more often than every other day. For most of patients an optimum dose are 0,5 mg twice a day. However reception on 1 mg 2 times a day is shown to some patients.
On reaching an optimum dose administration of drug can be recommended once a day.
Manias at bipolar disorders
The recommended initial dose of drug - 2 mg a day at one time. If necessary
this dose can be raised on 2 mg a day, not more often than every other day. For the majority
patients an optimum dose are 2-6 mg a day.
Disorders of behavior at patients with a delay of intellectual development
Patients, the weighing 50 kg and more - the recommended initial dose of drug - 0.5 mg in
put once. If necessary this dose can be raised on 0,5 mg a day, not more often
than every other day. For most of patients an optimum dose is the dose of 1 mg a day.
However reception on 0,5 mg a day whereas is more preferable to some patients
some need increase in a dose up to 1,5 mg a day.
Patients, the weighing less than 50 kg - the Recommended initial dose of drug - once put 0.25 mg. If necessary this dose can be raised on 0,25 mg a day, not more often than every other day. For most of patients an optimum dose is the dose of 0,5 mg a day. However reception on 0,25 mg a day whereas some need increase in a dose up to 0,75 mg a day is more preferable to some patients.
Long reception of Speridan at teenagers has to be carried out under constant control of the doctor.
Use for children is younger than 15 years it is not recommended.

Features of use:

Transition from therapy by other antipsychotic drugs. At schizophrenia, in an initiation of treatment risperidony, it is recommended to cancel gradually the previous therapy if it is clinically justified. If patients are transferred from therapy of depot by forms of antipsychotic drugs, then reception of a risperidon is recommended to be begun instead of the following planned injection. Periodically it is necessary to estimate need of continuation of therapy by potivoparkinsonichesky medicines. Due to and - orthostatic hypotension, especially during initial selection of a dose can arise adrenoceptor blocking action of a risperidon. When developing hypotonia it is necessary to consider a question of a dose decline. At patients with diseases of serdechnoksosudisty system, and also at dehydration, a hypovolemia or cerebrovascular disturbances, the dose should be increased gradually, according to recommendations (see the Route of administration and doses).
Emergence of extrapyramidal symptoms is risk factor for development of late dyskinesia. In case of signs and symptoms of late dyskinesia, it is necessary to consider a question of cancellation of all antipsychotic drugs. At emergence of the antipsychotic malignant syndrome which is characterized by a hyperthermia, muscular rigidity, instability of autonomous functions, disturbances of consciousness and increase in level of a kreatinfosfokinaza it is necessary to cancel all antipsychotic medicines, including рисперидон.
At cancellation of carbamazepine and other inductors of "hepatic" enzymes the dose of a risperidon has to be lowered.
Patients should recommend to refrain from an overeating in connection with a possibility of increase in body weight.
During treatment it is necessary to refrain from occupations potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions and also from alcohol intake.

Side effects:

From a nervous system: sleeplessness, agitation, alarm, a headache, sometimes - drowsiness, increased fatigue, dizziness, disturbance of concentration of attention, a sight ambiguity, it is rare - extrapyramidal symptoms (a tremor, rigidity, hypersalivation, a bradykinesia, an akathisia, acute dystonia), a mania or a hypomania, a stroke (at elderly patients with the contributing factors), and also a hypervolemia (either because of a polydipsia, or because of a syndrome of inadequate secretion of antidiuretic hormone), late dyskinesia (the involuntary rhythmic movements preferential of language and/or persons), an antipsychotic malignant syndrome (a hyperthermia, muscular rigidity, instability of autonomous functions, disturbance of consciousness and increase in level of a kreatinfosfokinaza), disturbances of thermal control and epileptic seizures. From the alimentary system: locks, dyspepsia, nausea or vomiting, an abdominal pain, increase in activity of "hepatic" transaminases, dryness in a mouth, hypo - or hypersalivation, anorexia and/or strengthening of appetite, increase or decrease in body weight. From cardiovascular system: sometimes orthostatic hypotension, reflex tachycardia or increase in arterial pressure. From bodies of a hemopoiesis: neutropenia, thrombocytopenia.
From endocrine system: a galactorrhoea, a gynecomastia, disturbance of a menstrual cycle, an amenorrhea, increase in body weight, a hyperglycemia and an aggravation of the diabetes mellitus existing earlier.
From urinogenital system: priapism, disturbances of an erection, disturbance of an ejaculation, anorgazmiya, urine incontience.
Allergic reactions: rhinitis, rash, Quincke's disease, photosensitization. From integuments: xeroderma, hyperpegmentation, itch, seborrhea. Other: arthralgia.

Interaction with other medicines:

Taking into account that рисперидон has effect first of all on the central nervous system, it should be applied with care in combination with other drugs of the central action and with alcohol.
Risperidon reduces efficiency of a levodopa and other agonists of dopamine. Clozapine reduces clearance of a risperidon.
When using carbamazepine decrease in concentration of active antipsychotic fraction of a risperidon in plasma was noted. Similar effects can be observed when using other inductors of liver enzymes. Fenotiazina, tricyclic antidepressants and some R-adrenoblockers can increase concentration of a risperidon in plasma, however it does not influence concentration of active antipsychotic fraction.
Fluoxetine can increase concentration of a risperidon in plasma, however to a lesser extent concentration of active antipsychotic fraction therefore doses of a risperidon should be adjusted.
At use of a risperidon together with other drugs highly contacting proteins of plasma, clinically expressed replacement of any drug from protein fraction of plasma is not observed.
Hypotensive medicines increase expressiveness of a lowering of arterial pressure against the background of a risperidon.

Contraindications:

Hypersensitivity to drug components; lactation period.
With care:
Diseases of cardiovascular system (chronic heart failure, the postponed myocardial infarction, disturbances of conductivity of a cardiac muscle) dehydration and a hypovolemia of disturbance of cerebral circulation Parkinson's disease of a spasm (including in the anamnesis)
heavy renal or liver failure (see recommendations about dosing)
abuse of medicines or medicinal dependence (see recommendations about dosing)
the states contributing to development of tachycardia like "pirouette" (bradycardia, disturbance of electrolytic balance, the accompanying reception of the medicines extending QT interval)
brain tumor, intestinal impassability, cases of acute overdose of drugs, syndrome to Reja (the antiemetic effect of a risperidon can mask symptoms of these states)
pregnancy, children's age up to 15 years (efficiency and safety are not established).
Use at pregnancy and a lactation. Safety of a risperidon at pregnant women was not studied. At pregnancy it is possible to use only if the positive effect justifies possible risk.
As рисперидон and 9-hydroxies-risperidon get into breast milk, the women using drug should not nurse.

Overdose:

Symptoms: drowsiness, sedation, consciousness oppression, tachycardia, arterial hypotension, extrapyramidal frustration, in rare instances lengthening of an interval of QT. Treatment: it is necessary to provide free passability of respiratory tracts for ensuring adequate oxygenation and ventilation, a gastric lavage (after an intubation if the unconscious patient) and purpose of absorbent carbon in a combination to purgatives. The symptomatic therapy directed to maintenance of the vital functions of an organism.
For timely diagnosing of possible disturbances of a heart rhythm it is necessary to begin monitoring of an ECG as soon as possible. Careful medical observation and an ECG carry out monitoring to total disappearance of symptoms of intoxication. The specific antidote is absent.

Storage conditions:

At a temperature not above 25 °C. To store in the place, unavailable to children! Period of validity 3 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

On 10 tablets in the blister (PVC/PVDH / aluminum foil). On 1 or 2 blisters together with the application instruction in a cardboard pack. On 10, 20, 40, 60 blisters together with application instructions in a cardboard box (for hospitals). "In balk" - on 300 tablets in a plastic bag, each bag in a plastic container.